News

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

An analysis of several datasets cataloguing the switch revealed that dosing can be extended up to 2 weeks for patients with nAMD who received prior anti-VEGF therapy.

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

A study reveals key risk factors for anaphylaxis from non-severe drug hypersensitivity, emphasizing the need for caution in drug administration.

The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Discover an approach to diagnosing food sensitivities, offering personalized diets and significant symptom relief through testing methods.

Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.

Notable psychosocial and occupational burdens, as well as impairments to emotional well-being, were seen among caregivers of adolescents with alopecia.

New research reveals older adults face higher anaphylaxis risks from medications and IV contrast, often presenting with severe symptoms and outcomes.

Findings suggest sleep disorders are common in PBC and are linked to worse biochemical markers, greater symptom burden, and reduced treatment response rates.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

Explore innovative strategies for asthma management that prioritize shared decision-making and address environmental, social, and behavioral factors.

MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

Najy Issa, MD, describes “underwhelming” universal HBV screening uptake since 2023 CDC guidelines were implemented and steps to get more patients screened.

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream's success in addressing unmet needs for atopic dermatitis.

A recent study reveals that anaphylaxis rates remain stable during the COVID-19 pandemic, despite reduced emergency visits.

A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for nAMD.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

In a recent review, experts answer frequent questions allergists have about conducting proximity challenges in patients with food allergy anxiety.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.

NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.